Clinical Observation of Erlotinib as the First-line Treatment for Patients with Advanced Non-small Cell Lung Cancer
Background and objective To evaluate the efficacy and toxicity of erlotinib as the first-line therapy for advanced non-small cell lung cancer (NSCLC). Methods A total of 28 pathologically-confirmed NSCLC patients who could not receive willingly or tolerate traditional cytotoxic drugs chemotherapy we...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Chinese Anti-Cancer Association; Chinese Antituberculosis Association
2009-12-01
|
| Series: | Chinese Journal of Lung Cancer |
| Subjects: | |
| Online Access: | http://www.lungca.org/index.php?journal=01&page=article&op=viewFile&path[]=10.3779%2Fj.issn.1009-3419.2009.12.11&path[]=1235 |
| _version_ | 1818333480307654656 |
|---|---|
| author | Yunjian HUANG Jing ZHANG Zhenwu XU Wu ZHUANG Biao WU Cheng HUANG |
| author_facet | Yunjian HUANG Jing ZHANG Zhenwu XU Wu ZHUANG Biao WU Cheng HUANG |
| author_sort | Yunjian HUANG |
| collection | DOAJ |
| description | Background and objective To evaluate the efficacy and toxicity of erlotinib as the first-line therapy for advanced non-small cell lung cancer (NSCLC). Methods A total of 28 pathologically-confirmed NSCLC patients who could not receive willingly or tolerate traditional cytotoxic drugs chemotherapy were enrolled. Erlotinib was orally administered 150 mg daily until disease progression or the occurrence of intolerable toxicity. Results Among a total of 28 patients, the objective response rate (ORR) of erlotinib was 28.6%. The disease control rate (DCR) was 60.7%. The rate of symptom relief was 53.6%. The median progression free survival (PFS) was 3.2 (95%CI: 0.851-5.585) months. The median overall survival (OS) was 9.6 (95%CI: 7.179-12.021) months. One-year survival rate was 32.1%. The therapeutic effect was better in patients with rash. Most of the toxicities were grade I and grade II toxicity. The most common adverse events were rash (46.4%), diarrhea (32.1%), skin dry (25.0%), anorexia(17.9%), fatigue (10.7%) and increased transaminase (7.1%). Conclusion Erlotinib provided another choice for the patients who could not willingly receive or tolerate chemotherapy. |
| first_indexed | 2024-12-13T13:52:18Z |
| format | Article |
| id | doaj.art-72c8e59a848d4dcfa45f2e2be7821512 |
| institution | Directory Open Access Journal |
| issn | 1009-3419 1999-6187 |
| language | zho |
| last_indexed | 2024-12-13T13:52:18Z |
| publishDate | 2009-12-01 |
| publisher | Chinese Anti-Cancer Association; Chinese Antituberculosis Association |
| record_format | Article |
| series | Chinese Journal of Lung Cancer |
| spelling | doaj.art-72c8e59a848d4dcfa45f2e2be78215122022-12-21T23:43:05ZzhoChinese Anti-Cancer Association; Chinese Antituberculosis AssociationChinese Journal of Lung Cancer1009-34191999-61872009-12-01121212821286Clinical Observation of Erlotinib as the First-line Treatment for Patients with Advanced Non-small Cell Lung CancerYunjian HUANGJing ZHANGZhenwu XUWu ZHUANGBiao WUCheng HUANGBackground and objective To evaluate the efficacy and toxicity of erlotinib as the first-line therapy for advanced non-small cell lung cancer (NSCLC). Methods A total of 28 pathologically-confirmed NSCLC patients who could not receive willingly or tolerate traditional cytotoxic drugs chemotherapy were enrolled. Erlotinib was orally administered 150 mg daily until disease progression or the occurrence of intolerable toxicity. Results Among a total of 28 patients, the objective response rate (ORR) of erlotinib was 28.6%. The disease control rate (DCR) was 60.7%. The rate of symptom relief was 53.6%. The median progression free survival (PFS) was 3.2 (95%CI: 0.851-5.585) months. The median overall survival (OS) was 9.6 (95%CI: 7.179-12.021) months. One-year survival rate was 32.1%. The therapeutic effect was better in patients with rash. Most of the toxicities were grade I and grade II toxicity. The most common adverse events were rash (46.4%), diarrhea (32.1%), skin dry (25.0%), anorexia(17.9%), fatigue (10.7%) and increased transaminase (7.1%). Conclusion Erlotinib provided another choice for the patients who could not willingly receive or tolerate chemotherapy.http://www.lungca.org/index.php?journal=01&page=article&op=viewFile&path[]=10.3779%2Fj.issn.1009-3419.2009.12.11&path[]=1235ErlotinibLung neoplasmsFirst-line therapy |
| spellingShingle | Yunjian HUANG Jing ZHANG Zhenwu XU Wu ZHUANG Biao WU Cheng HUANG Clinical Observation of Erlotinib as the First-line Treatment for Patients with Advanced Non-small Cell Lung Cancer Chinese Journal of Lung Cancer Erlotinib Lung neoplasms First-line therapy |
| title | Clinical Observation of Erlotinib as the First-line Treatment for Patients with Advanced Non-small Cell Lung Cancer |
| title_full | Clinical Observation of Erlotinib as the First-line Treatment for Patients with Advanced Non-small Cell Lung Cancer |
| title_fullStr | Clinical Observation of Erlotinib as the First-line Treatment for Patients with Advanced Non-small Cell Lung Cancer |
| title_full_unstemmed | Clinical Observation of Erlotinib as the First-line Treatment for Patients with Advanced Non-small Cell Lung Cancer |
| title_short | Clinical Observation of Erlotinib as the First-line Treatment for Patients with Advanced Non-small Cell Lung Cancer |
| title_sort | clinical observation of erlotinib as the first line treatment for patients with advanced non small cell lung cancer |
| topic | Erlotinib Lung neoplasms First-line therapy |
| url | http://www.lungca.org/index.php?journal=01&page=article&op=viewFile&path[]=10.3779%2Fj.issn.1009-3419.2009.12.11&path[]=1235 |
| work_keys_str_mv | AT yunjianhuang clinicalobservationoferlotinibasthefirstlinetreatmentforpatientswithadvancednonsmallcelllungcancer AT jingzhang clinicalobservationoferlotinibasthefirstlinetreatmentforpatientswithadvancednonsmallcelllungcancer AT zhenwuxu clinicalobservationoferlotinibasthefirstlinetreatmentforpatientswithadvancednonsmallcelllungcancer AT wuzhuang clinicalobservationoferlotinibasthefirstlinetreatmentforpatientswithadvancednonsmallcelllungcancer AT biaowu clinicalobservationoferlotinibasthefirstlinetreatmentforpatientswithadvancednonsmallcelllungcancer AT chenghuang clinicalobservationoferlotinibasthefirstlinetreatmentforpatientswithadvancednonsmallcelllungcancer |